Clearpoint Neuro, Inc. (CLPT)
NASDAQ:CLPT
Want to see CLPT full AI Analyst Report?
Top Page
ClearPoint Neuro
(NASDAQ:CLPT)
Select Model
Select Model
Rating:49Neutral
Price Target:
$12.50
▼(-54.25% Downside)
Action:Reiterated
Date:05/22/26
The score is held back primarily by weak financial quality—ongoing large losses, negative free cash flow, and sharply higher leverage—despite strong revenue growth and solid gross margins. The earnings call adds support through reaffirmed guidance and clear commercial momentum, while technicals and valuation are mixed and do not offset the fundamental cash-burn and balance-sheet risk.
Positive Factors
Revenue Growth & Adoption
Sustained double-digit top-line growth off a growing installed base indicates expanding clinical adoption and stronger procedure volume potential. Organic device growth and recurring consumable pull-through make revenue more durable, supporting scalable recurring revenue as installations increase over the next several quarters.
Negative Factors
Rising Leverage
Sharply higher leverage reduces financial flexibility and raises refinancing and covenant risk while the business remains unprofitable. A heavy debt load constrains capital allocation, increases interest sensitivity, and heightens the consequences of any slower-than-expected revenue or synergies realization over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth & Adoption
Sustained double-digit top-line growth off a growing installed base indicates expanding clinical adoption and stronger procedure volume potential. Organic device growth and recurring consumable pull-through make revenue more durable, supporting scalable recurring revenue as installations increase over the next several quarters.
Read all positive factors
ClearPoint Neuro (CLPT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$379.97M
Dividend YieldN/A
Average Volume (3M)561.17K
Price to Earnings (P/E)―
Beta (1Y)1.91
Revenue Growth25.99%
EPS Growth-33.84%
CountryUS
Employees115
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.01
Shares Outstanding29,989,563
10 Day Avg. Volume613,778
30 Day Avg. Volume561,169
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)13.82
Price to Sales (P/S)10.48
P/FCF Ratio-15.84
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue10.04
Enterprise Value/Gross Profit16.25
Enterprise Value/Ebitda-17.04
Forecast
1Y Price Target
$22.00Price Target Upside-19.47% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.98
Revenue Forecast (FY)$53.13M
ClearPoint Neuro Business Overview & Revenue Model
Company Description
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural mag...
How the Company Makes Money
ClearPoint Neuro primarily generates revenue by selling and supporting its neurosurgical navigation platform and the consumables used with it. Key revenue streams typically include: (1) capital equipment sales (and/or placements) of the ClearPoint...
ClearPoint Neuro Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call presented a predominantly positive commercial and strategic update: record Q1 revenue (+43% YoY), improved gross margin (64%), significant product and regulatory milestones (PRISM expansion, Velocity drill FDA clearance and CE marking), and visible IRRAflow integration progress and synergies. These positives are tempered by meaningful near-term cash reduction and a $8M operational burn in Q1 plus elevated operating expenses (R&D +34%, S&M +75%, G&A +22%) largely tied to growth investments and integration. Management forecasts a return to improved cash consumption as integration completes and reiterated full-year revenue guidance of $52M–$56M. Regulatory uncertainty on the biologics side and temporary OUS distribution transitions introduce timing risk for some programs, while biologics/drug delivery revenue remained essentially flat (+2%) this quarter. Overall, the fundamentals and strategic momentum outweigh the near-term financial and operational headwinds.Positive Updates
Record Quarterly Revenue and Strong YoY Growth
Total revenue of $12.1M in Q1 2026 vs $8.5M in Q1 2025, representing 43% year-over-year growth; management also reported 16% organic growth and device-organic growth of 25%.
Negative Updates
Cash Reduction and Operational Burn
Cash and cash equivalents decreased to $35.6M as of March 31, 2026 from $45.9M at December 31, 2025; operational cash burn was $8M in Q1 2026 plus ~$2M related to tax payments for net share settlement of equity awards.
Read all updates
Q1-2026 Updates
Positive
Negative
Record Quarterly Revenue and Strong YoY Growth
Total revenue of $12.1M in Q1 2026 vs $8.5M in Q1 2025, representing 43% year-over-year growth; management also reported 16% organic growth and device-organic growth of 25%.
Read all positive updates
Company Guidance
ClearPoint reiterated 2026 revenue guidance of $52–$56 million, citing a strong start with Q1 record revenue of $12.1 million (up 43% YoY; 16% organic growth; organic devices +25%), gross margin of 64% (vs 60% in Q1 2025), and cash of $35.6 million as of 3/31/26 (down from $45.9M due to $8M operational cash burn in Q1 plus ~$2M tax payments); management expects sequential quarter-over-quarter revenue growth for the year, double-digit growth across each of the four pillars in 2026, the IRRAflow business to represent roughly 20–25% of revenue by year-end and potentially be cash neutral as early as 2027, the site base to grow from >175 active sites today to >200 by end of 2026, and operational cash burn to decrease as IRRAS integration completes.ClearPoint Neuro Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
22
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.61M | 36.97M | 31.39M | 23.95M | 20.55M | 16.30M |
| Gross Profit | 25.11M | 22.69M | 19.12M | 13.61M | 13.53M | 11.12M |
| EBITDA | -23.94M | -21.93M | -17.84M | -20.99M | -15.58M | -12.74M |
| Net Income | -29.07M | -25.54M | -18.91M | -22.09M | -16.43M | -14.41M |
Balance Sheet | ||||||
| Total Assets | 93.42M | 97.75M | 39.19M | 42.66M | 55.49M | 65.58M |
| Cash, Cash Equivalents and Short-Term Investments | 35.59M | 45.92M | 20.10M | 23.14M | 37.49M | 54.11M |
| Total Debt | 63.59M | 58.23M | 3.57M | 13.94M | 11.99M | 12.28M |
| Total Liabilities | 74.58M | 69.73M | 13.80M | 21.49M | 18.60M | 16.79M |
| Stockholders Equity | 18.84M | 28.02M | 25.39M | 21.17M | 36.89M | 48.79M |
Cash Flow | ||||||
| Free Cash Flow | -26.70M | -24.45M | -9.22M | -14.44M | -16.42M | -12.87M |
| Operating Cash Flow | -25.72M | -23.93M | -8.95M | -13.72M | -16.17M | -12.70M |
| Investing Cash Flow | 153.00K | 615.00K | -275.00K | 8.95M | -10.74M | -168.00K |
| Financing Cash Flow | 49.70M | 50.18M | 6.19M | 296.00K | 409.00K | 46.88M |
ClearPoint Neuro Technical Analysis
Positive
27.32
Price Trends
10.70
Positive
11.94
Positive
14.14
Negative
Market Momentum
0.28
Negative
59.64
Neutral
57.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLPT, the sentiment is Positive. The current price of 27.32 is above the 20-day moving average (MA) of 11.80, above the 50-day MA of 10.70, and above the 200-day MA of 14.14, indicating a neutral trend. The MACD of 0.28 indicates Negative momentum. The RSI at 59.64 is Neutral, neither overbought nor oversold. The STOCH value of 57.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLPT.
ClearPoint Neuro Risk Analysis
ClearPoint Neuro disclosed 56 risk factors in its most recent earnings report. ClearPoint Neuro reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ClearPoint Neuro Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $710.88M | 20.11 | 16.27% | ― | 1.52% | ― | |
61 Neutral | $625.32M | -37.12 | -9.56% | ― | 16.77% | 39.26% | |
58 Neutral | $1.16B | -16.58 | -8.91% | ― | 3.87% | 80.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $379.97M | -12.88 | -140.96% | ― | 25.99% | -33.84% | |
47 Neutral | $374.71M | -6.25 | -13.44% | ― | 2.59% | 59.39% |
* Healthcare Sector Average
CLPT
ClearPoint Neuro
12.67
0.88
7.46%
OFIX
Orthofix Medical
9.27
-1.57
-14.48%
AVNS
Avanos Medical
24.80
12.72
105.30%
SIBN
SI-Bone
14.10
-4.76
-25.24%
BVS
Bioventus
8.51
2.07
32.14%
ClearPoint Neuro Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
ClearPoint Neuro Shareholders Approve Incentive Plan and Directors
Positive
May 21, 2026
At its annual meeting on May 20, 2026, ClearPoint Neuro stockholders approved the Seventh Amended and Restated 2013 Incentive Compensation Plan, aligning with prior adoption by the board and reinforcing the company’s equity-based compensatio...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
ClearPoint Neuro Posts Strong Q1 Growth, Reaffirms 2026 Outlook
Positive
May 13, 2026
On May 13, 2026, ClearPoint Neuro reported first-quarter 2026 revenue of $12.1 million, up 43% year over year, including 16% organic growth and contribution from the recently acquired IRRAflow portfolio. The company’s activated installed bas...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsPrivate Placements and Financing
ClearPoint Neuro Reports Record 2025 Results, Expands Growth Outlook
Positive
Mar 17, 2026
ClearPoint Neuro, Inc., based in Solana Beach, Calif., is a global medical device and therapy-enabling company focused on precise navigation for the brain and spine. Its portfolio spans biologics and drug delivery tools, neurosurgery navigation an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.